ArticleInternational journal of hematology2009
Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients.
Article in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.The Cochrane database of systematic reviews · 2019Pooled it
- Galactomannan detection for invasive aspergillosis in immunocompromised patients.The Cochrane database of systematic reviews · 2015Pooled it
- Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis.PloS one · 2012Pooled it
- Sputum signatures for invasive pulmonary aspergillosis in patients with underlying respiratory diseases (SPARED): study protocol for a prospective diagnostic trial.BMC infectious diseases · 2018Trial
- Article
- Review of the Microbial Spectrum of Mixed Respiratory Fungal Infections.Journal of epidemiology and global health · 2026Review
- Invasive Aspergillosis in the Intensive Care Unit.Journal of fungi (Basel, Switzerland) · 2025Review
- Fungal infections in liver cirrhosis.Translational gastroenterology and hepatology · 2024Review
- Microbiological Non-Culture-Based Methods for Diagnosing Invasive Pulmonary Aspergillosis in ICU Patients.Diagnostics (Basel, Switzerland) · 2023Review
- Performance of galactomannan testing from endotracheal aspirate to guide bronchoalveolar lavage in the diagnosis of invasive aspergillosis.Infection · 2023Article
- Article
- Sputum Galactomannan Has Utility in the Diagnosis of Chronic Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2022Article
- Comparative Analysis of Clinical Parameters and Sputum Biomarkers in Establishing the Relevance of Filamentous Fungi in Cystic Fibrosis.Frontiers in cellular and infection microbiology · 2020Article
- Diagnostic Accuracy of Bronchoalveolar Lavage Fluid Galactomannan for Invasive Aspergillosis.BioMed research international · 2020Article
- Role of theFrontiers in microbiology · 2019Article
- Aspergillus fumigatus Detection and Risk Factors in Patients with COPD-Bronchiectasis Overlap.International journal of molecular sciences · 2018Article
- Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.Clinics in chest medicine · 2017Review
- Current challenges in the microbiological diagnosis of invasive aspergillosis.Mycopathologia · 2014Review
- Identification and management of invasive mycoses in internal medicine: a road-map for physicians.Internal and emergency medicine · 2014Review
- Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.Scientifica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the diagnostic utility of Aspergillus galactomannan (GM) in sputum for diagnosis of invasive pulmonary aspergillosis (IPA) in haematologic patients and compared the results with those of bronchial lavage fluid (BLF) and serum. Patients were classified into 4 groups using modified European Organization for Research and Treatment of Cancer criteria: group A, proven IPA; group B, probable IPA; group C, possible IPA; group D, others. Groups A and B were considered the IPA group (n = 6); group D was considered non-IPA group (n = 37); group C (n = 13) was equivocal for IPA. As a true negative control, sputa from patients with community-acquired pneumonia (CAP) without risk factors (group E, n = 22) were used. From the receiver-operating characteristic curves, the cut-off levels were determined as 1.2 in sputum, 0.5-1.3 in BLF and 0.5 in serum. The sensitivity and specificity of sputum, BLF and serum GM were 100 and 62.2%, 66.7 and 100%, and 83.3 and 81.1%, respectively. Twenty-two patients with CAP (group E) showed median GM levels in the sputa of 0.1 (range 0.0-1.0). Sputum GM is a useful non-invasive test for screening of IPA in haematological patients, and may also be useful for assessment of the risk of developing IPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.